Crossmark

Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes

Crossref DOI link: https://doi.org/10.1007/s40744-021-00418-5

Published Online: 2022-02-03

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Feist, Eugen http://orcid.org/0000-0002-9872-5282
Baraliakos, Xenofon http://orcid.org/0000-0002-9475-9362
Behrens, Frank http://orcid.org/0000-0001-8750-7186
Thaçi, Diamant http://orcid.org/0000-0001-8513-550X
Klopsch, Thilo

Plenske, Anja

Blindzellner, Lisa K. http://orcid.org/0000-0002-6203-5095
Klaus, Pascal

Meng, Thomas

Löschmann, Peter-Andreas http://orcid.org/0000-0002-3518-0174
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02486302 at ClinicalTrials.gov

Documents that mention this clinical trial

Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
https://doi.org/10.1007/s40744-021-00418-5

Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE
https://doi.org/10.1007/s40744-023-00633-2
Funding

Funding for this research was provided by:

Pfizer
License Information

Text and Data Mining valid from 2022-02-03

Version of Record valid from 2022-02-03
More Information

Article History

Received: 28 September 2021

Accepted: 14 December 2021

First Online: 3 February 2022

Change Date: 5 September 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40744-023-00578-6

Updates are available Correction dated 2023-09-05

Click to view Correction: https://doi.org/10.1007/s40744-023-00578-6